Recombinant Adenovirus Vector Vaccine Studies

National Institute Of Allergy And Infectious Diseases

Investigators

Linked publications & trials

Abstract

Adenovirus vectors have shown promise for vaccines, but one key hurdle is preexisting immunity to these viruses in humans. The VRC has been investigating the use of DNA priming and the use of alternate adenoviral serotypes or modified adenoviral vectors to overcome prior immunity. During the past year, the VRC has evaluated various serotypes, including Ad 26, 28 and non human primate adenoviral serotype vectors to analyze their ability to induce an immune response as compared to Ad5 and in the presence of Ad5 seropostivity. Several of these vectors are being further tested to evaluate their potential use in clinical trials.